Scancell Holdings plc (SCLP.L) LSE

Currency In GBp

Scancell Holdings plc

Address

Unit 202 Bellhouse Building

Oxford, OX4 4GD

United Kingdom of Great Britain and Northern Ireland (the)

Phone

44 18 6558 2066

Website

https://www.scancell.co.uk

Sector

Healthcare

Industry

Biotechnology

Employees

First IPO Date

February 12, 2010

Key Executives

Name	Title	Pay	Year Born
Phillip John L'Huillier	Chief Executive Officer & Director	391,966	1962
Lindy Gillian Durrant	Chief Scientific Officer, Director & Founder	386,797	1957
Callum Scotthasbeen	Senior Vice President of Development	0	N/A
Mandeep Sehmi	Head of Business Development	0	N/A
Nermeen Varawalla DPHIL	Chief Medical Officer	0	1962
Samantha Paston	Head of Translational Research	0	N/A
Shamim Kazmi Stokes	Head of Programme Management	0	N/A
Alex Hayward	Finance Director & Company Secretary	0	N/A
David Schilansky	Interim Chief Financial Officer	0	1975
Philip Angell-Manning	Head of CMC	0	N/A

Description

Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious diseases. The company's pipeline features several promising candidates, including SCIB1, currently in Phase II clinical trials for metastatic melanoma; SCIB2, aimed at non-small cell lung cancer; and Modi-1, which is undergoing Phase I/II studies for various indications such as head and neck, triple-negative breast, ovarian, and renal cancers. Additionally, Scancell is advancing Modi-2, a therapeutic agent specifically designed to target homocitrullinated cancer antigens. Its development efforts also encompass SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine engineered to provide protection against the SARS-CoV-2 virus. Founded in 1997, Scancell Holdings plc is headquartered in Oxford, United Kingdom.